These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 16483784)
1. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784 [TBL] [Abstract][Full Text] [Related]
2. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound. Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Skotnicki JS; Wilhelm J; Powers R Biochemistry; 1999 Jun; 38(22):7085-96. PubMed ID: 10353819 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies. Moroy G; Denhez C; El Mourabit H; Toribio A; Dassonville A; Decarme M; Renault JH; Mirand C; Bellon G; Sapi J; Alix AJ; Hornebeck W; Bourguet E Bioorg Med Chem; 2007 Jul; 15(14):4753-66. PubMed ID: 17512742 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835 [TBL] [Abstract][Full Text] [Related]
5. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126 [TBL] [Abstract][Full Text] [Related]
6. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2. Jani M; Tordai H; Trexler M; Bányai L; Patthy L Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326 [TBL] [Abstract][Full Text] [Related]
7. A novel series of highly selective inhibitors of MMP-3. Whitlock GA; Dack KN; Dickinson RP; Lewis ML Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Cheng XC; Wang Q; Fang H; Tang W; Xu WF Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232 [TBL] [Abstract][Full Text] [Related]
9. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. Nar H; Werle K; Bauer MM; Dollinger H; Jung B J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929 [TBL] [Abstract][Full Text] [Related]
10. QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase. Jamloki A; Karthikeyan C; Hari Narayana Moorthy NS; Trivedi P Bioorg Med Chem Lett; 2006 Jul; 16(14):3847-54. PubMed ID: 16682189 [TBL] [Abstract][Full Text] [Related]
11. Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Cheng XC; Wang Q; Fang H; Tang W; Xu WF Bioorg Med Chem; 2008 Sep; 16(17):7932-8. PubMed ID: 18718763 [TBL] [Abstract][Full Text] [Related]
12. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors. Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829 [TBL] [Abstract][Full Text] [Related]
14. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of new tripeptide phosphonate inhibitors of MMP-8 and MMP-2. Agamennone M; Campestre C; Preziuso S; Consalvi V; Crucianelli M; Mazza F; Politi V; Ragno R; Tortorella P; Gallina C Eur J Med Chem; 2005 Mar; 40(3):271-9. PubMed ID: 15725496 [TBL] [Abstract][Full Text] [Related]
17. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13. Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229 [TBL] [Abstract][Full Text] [Related]
18. A combined molecular modeling study on gelatinases and their potent inhibitors. Xi L; Du J; Li S; Li J; Liu H; Yao X J Comput Chem; 2010 Jan; 31(1):24-42. PubMed ID: 19412908 [TBL] [Abstract][Full Text] [Related]